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Background: Poor attendance to cervical cancer (CC) screening is a major risk factor for CC. Efforts to capture
underscreened women are considerable and once women agree to participate, the provision of longitudinal
validity of the screening test is of paramount relevance. We evaluate the addition of high risk HPV test (HPV) to
cervical cytology as a primary screening test among underscreened women in the longitudinal prediction of
intraepithelial lesions grade 2 or worse (CIN2+).
Methods: Women were included in the study if they were older than 39 years and with no evidence of cervical
cytology in the previous five years within the Public Primary Health Care System in Catalonia (Spain). 1,832
underscreened women from eight public primary health areas were identified during 2007–2008 and followed-up
for over three years to estimate longitudinal detection of CIN2+. Accuracy of each screening test and the combination
of both to detect CIN2+ was estimated. The risk of developing CIN2+ lesions according to histology data by cytology
and HPV test results at baseline was estimated using the Kaplan–Meier method.
Results: At baseline, 6.7% of participants were HPV positive, 2.2% had an abnormal cytology and 1.3% had both tests
positive. At the end of follow-up, 18 out of 767 (2.3%) underscreened women had a CIN2+, two of which were invasive
CC. The three-year longitudinal sensitivity and specificity estimates to detect CIN2+ were 90.5% and 93.0% for HPV test
and 38.2% and 97.8% for cytology. The negative predictive value was >99.0% for each test. No additional gains in
validity parameters of HPV test were observed when adding cytology as co-test. The referral to colposcopy was higher
for HPV but generated 53% higher detection of CIN2+ compared to cytology.
Conclusions: Underscreened women had high burden of cervical disease. Primary HPV screening followed by
cytology triage could be the optimal strategy to identify CIN2+ leading to longer and safe screen intervals.
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Infection with high-risk human papillomavirus types
(HPV) is the necessary cause for the development of
cervical cancer (CC) [1]. Historically, organized screening
using cytology at regular intervals with a high coverage
has reduced the incidence of invasive CC in many coun-
tries [2,3]. Absence or poor screening history remains the* Correspondence: raquelip@iconcologia.net
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unless otherwise stated.major risk factor for CC, and can contribute to over half
of CC cases [4-9].
Primary CC screening with HPV detection has been
shown in randomized controlled trials (RCTs) to have
higher longitudinal sensitivity to detect cervical intrae-
pithelial neoplasia grade 2 or worse (CIN2+) than conven-
tional cytology, maintaining a high negative predictive
value (NPV) [10-14].
In the Autonomic region of Catalonia (Spain), routine
screening with cervical cytology is recommended to wo-
men aged 25–65 with a 3-year interval. Although scree-
ning is opportunistic, within the Public Health SystemLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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screened women have been established [15]. These activ-
ities are facilitated by raising awareness and a campaign
was launched amongst midwives, gynaecologists and fam-
ily practitioners to identify poorly screened women when
visiting Primary Health Care services. Women identified
as being underscreened were offered a screening visit that
included co-testing with HPV testing and cervical cytology
in order to assure the highest accuracy of the visit. The ra-
tionale was based on the very high sensitivity and high
NPV of joint testing for an extended period of three years
[10-14].
The aim of this study was to evaluate the addition of
HPV test to cervical cytology as a primary screening test
among the underscreened population in the longitudinal
prediction of CIN2+.Methods
1,832 women older than 39 years old were included.
Women were selected if they had no evidence of cervical
cytology in the public primary health registries in the
previous five years. Women identified in eight public
primary health areas of Catalonia during 2007 and 2008
were included in this study and followed-up until June
2012 (Figure 1). These women categorized as being
underscreened for CC were offered cytology and HPV
test at recruitment. If both tests were negative, follow-
up was recommended every 3 years until age 65. Women
were referred to colposcopy if either test was positive.
Women older than 65 years old and with both negative
tests exited the screening activity [15].Figure 1 Flowchart for the selection of the study population. Undersc
no records on cervical cytology during the previous five years. CIN2+: cerviThe pathology laboratories (Hospital Universitari Dr.
Josep Trueta, Consorci hospitalari de Vic, Hospital
Universitari Joan XXIII, Hospital del Mar, Hospital
Universitari de Bellvitge, Hospital General de Granollers,
Hospital d’Althaia and Laboratori d’Atenció Primària Dr.
Robert) provided information on age, results and date of
cytologies, histologies and HPV tests during the study
period for each woman. The overall project was approved
by the ethical committee of the Catalan Institute of
Oncology. Any information regarding the identification of
patients was anonymized before analysis.Screening tests
HPV detection was performed with the FDA-approved
Hybrid Capture 2 test (HC2; Qiagen, Gaithersburg,
MD, USA) which detects 13 high-risk HPV types
(16,18,31,33,35,39,45,51,52,56,58,59 and 68). An HPV
sample was considered positive if attained or exceeded
the FDA-approved threshold of 1.0 pg HPV DNA ml−1,
which corresponds to 1.0 relative light unit (RLU/CO).
All HPV reference laboratories participated in an inter-
laboratory quality control with kappa values over 90%
[16].
Cytologies were performed largely with conventional
Pap smears. Few centres used liquid based cervical cy-
tology and in such cases the HPV and the cytology was
performed in the same sample. All the cytological results
were classified according to the 2001 Bethesda system
[17]. Abnormal or positive cytology was defined as atypical
squamous cell of undetermined significance (ASC-US) or
more severe cytological diagnosis.reened women are defined as women older than 39 years and with
cal intraepithelial neoplasia grade 2 or worse.
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logical results [18].
Follow-up
The end-point of follow-up was established at the mo-
ment of the most severe diagnosis or June 2012. For
women with a positive test during the study period, a
final diagnosis of “normal” was assigned if at least two
negative tests were registered in subsequent visits. For
women with both tests negative at baseline a subsequent
negative test was requested to be categorised as being
negative for CIN2+.
When concomitant cytological and histological results
were available, the highest histological grade of abnor-
mality was used for the final diagnosis. Women not
having any additional test to those obtained at baseline
were considered as lost to follow-up.
Statistical analysis
Whenever appropriate, estimates are presented by
different combinations of screening tests results.
Three year longitudinal sensitivity, specificity, positive
predictive value (PPV) and NPV for CIN2+ detection
and their 95% CI were calculated for cytology, HPV
test and the combination of both. Estimates were
corrected taking into account the proportion of women
who returned to the next screening round in each screening
strata of results as reported elsewhere [19]. We estimated
the risk of developing CIN2+ lesions according to histology
data by cytology and HPV test result at baseline using the
Kaplan–Meier method.
Results
At baseline, the average age among the 1,832 included
women was 54.1 years (range 40–88 years). Most of
them (92.4%) had both tests negative. 338 women were
relieved from further screening because of being 65 years
old or older and had both tests negatives, leaving 1,494
undescreened women to be followed-up. Of them, 767
women (51.3%) completed follow-up. Lost to follow-up
was higher in women with both tests negative when
compared to those with at least one positive test
(p < 0.05) (Figure 1). Increasing age was significantly
associated with decreasing attendance to next screening
visit (data not shown).
Positive cytology was registered in 2.2% and HPV posi-
tivity in 6.7% of the women while 1.3% had both test
positive. Among HPV positive women, 19.5% had an ab-
normal cytology. Table 1 summarizes baseline and end
of study diagnosis. At the end of follow-up nine CIN2,
seven CIN3 and two invasive CC were diagnosed (18/
767, 2.3%) and histologically confirmed. All but one
CIN2+ were diagnosed among HPV positive women.
The two CC detected corresponded to one squamouscell carcinoma (stage II) and one adenocarcinoma (stage
I) and had as a baseline cytology diagnosis of ASC-US
and of atypical glandular cells of undetermined signifi-
cance respectively. Nine out of CIN2/3 identified during
follow-up had a normal cytology at entry. The mean
time between the first positive HPV test and the diagno-
sis of CIN2+ was 11.7 months. Among women HPV
negative at enrolment 96.2% persisted as negative.
At the end of follow-up, 27 women were classified as
having non-HPV related diseases including three endo-
metrial carcinoma cases, five leiomyomatosis and two
uterine prolapses within the HPV negative strata. Among
the HPV positive, 15 women had a persistent HPV infec-
tion with no further cytology data and one had a diagnosis
of uterine prolapse.
At 36 months, the cumulative detection of CIN2+ in
women with normal cytology and HPV positive at base-
line was 14.5% and 39.3% in women with both tests
being positive (Figure 2).
The longitudinal sensitivity of the HPV test was con-
siderably higher than that of cytology and equal to the
combination of both tests for histologically confirmed
CIN2+ (90.5; CI 95% = 88.8-92.2) (Table 2). Specificity
and PPV were both higher for cytology than HPV alone
or co-testing. NPV was high for both tests.
Discussion
CC screening activities aim to reach asymptomatic women
in specific target ages on regular basis. The organization
of these activities and the quality control measures are
crucial to optimize the resources for the best health bene-
fits. Irrespective of the type of the screening offered, poor
attendance by some and over use of the system by others
are persistent issues that need to be addressed. Our princi-
pal aim was to identify among poorly screened women in
a single screening visit any possible cervical intraepithelial
lesion that could lead to cancer. To provide the best opti-
mal detection at the time of the visit, HPV was offered as
an ancillary test to the cytology to increase longitudinal
sensitivity with a minimal impact in specificity. This inter-
vention differed from that given to the regular users of
screening facilities in which only cytology was offered
every three years or two consecutive cytologies within one
year if it was the first screening visit [15].
Co-testing with HPV referred 7.6% of underscreened
women for an either closer follow-up or to immediate
colposcopy. If we had used previous guidelines, in which
cytology was the screening test, all the women with a first
normal cytology at baseline (97.8%) had to be screened
again within a year in order to correct for poor cytology
sensitivity. This was not implemented in our population
because of the co-testing recommendation.
Positive cytology was detected in 2.2% of the women,
percentage that was overall similar to that observed in
Table 1 Diagnosis at follow-up among underscreened women by HPV status and concomitant cytology at baseline
























Normal 1693 (99.1)d 654 (98.2) 641 (98.3)e 1 (100) 1 (100) 1 (100)f 10 (90.9)
ASC-US/ASC H/AGC/LSIL 15 (0.8) 11 (1.7) 10 (1.5) 1 (9.1)
Suspected adenocarcinomag 1 (0.1) 1 (0.2) 1 (0.2)
TOTAL 1709 (100) 666 (100) 652 (100) 1 (100) 1 (100) 1 (100) 11 (100)









Normal 99 (80.5)d 78 (77.2) 45 (83.3) 6 (100) 2 (25.0) 6 (75) 3(42.9) 16 (100)
ASC-US/AGC/LSIL 19 (15.4) 18 (17.8) 9 (16.7) 5 (62.5) 1 (12.5) 1 (14.3) 2 (100)
HSIL 5 (4.1) 5 (5.0) 1 (12.5) 1 (12.5) 3 (42.9)
TOTAL 123 (100) 101 (100) 54 (100) 6 (100) 8 (100) 8 (100) 7 (100) 2 (100) 16 (100)
aAll the CIN1, CIN2, CIN3 and cervical cancer cases was histologically confirmed.
bOne of the cases was an infiltrating squamous carcinoma (stage II) diagnosed at 23 months after cytology and HPV testing at baseline. The other case was an adenocarcinoma (stage I) diagnosed one month after
study entry.
cAmong negative HPV women, there were 3 cases of endometrial carcinoma who underwent a hysterectomy, 7 hysterectomies (5 for leiomyomatosis and 2 for prolapse) and one case with second positive HPV test.
Among positive HPV women, there were a case with a hysterectomy for prolapse and 15 women with a persistent HPV infection.
dThere were included in this group 23 women whose concomitant cytology at baseline had unsatisfactory results but during the follow up period, all subsequent tests were negative. There was one case in HPV
positive arm.
eTwo cases with normal concomitant and negative HPV test at baseline developed endometrial carcinoma during the follow-up period, but follow-up cytologies were normal. Another case with normal concomitant
cytology and negative HPV test developed a VIN3 although Pap smears performed during the follow-up period were normal
fCIN2 was developed after 54 months of cytology and HPV testing at baseline. Conisation was performed but no further data was available.
gFinally the suspected of adenocarcinoma was a endometrial carcinoma, but follow-up cytologies were normal.
ASC-US: Atypical squamous cell of undetermined significance, ASC-H: Atypical squamous cells cannot exclude a high grade squamous intraepithelial lesion, AGC: Atypical glandular cells of undetermined significance,
HPV+: positive for Human Papillomavirus test, CIN-NOS: CIN not otherwise specified, CIN1: high grade cervical intraepithelial lesions grade 1, LSIL: low grade squamous intraepithelial lesion, CIN1: high grade cervical
































Figure 2 Cumulative detection of CIN2+ according to baseline result of cytology and HPV testing. Detection of CIN2+ in underscreened
women based on 767 women. Women were classified into 4 groups depending on the HPV and cytology results at baseline. Note that there is a
higher risk of development CIN2+ in positive HPV women with normal cytology.
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though lesions in our study were more severe than ex-
pected [20]. However, by using HPV test, 6.7% of the
women were positive but we identified over 50% more
CIN2+ in the three years following the index screening
visit than with the solely use of cytology. The difference
in cumulative risk of CIN2+ for those with a double
negative tests results compared to those with a HPV-
negative test was minimal (0.2%) supporting the fact
that, in this population, single testing with HPV could be
sufficient as the first screening test. These results were
consistent with the state of the art knowledge provided
by several RCTs comparing clinically validated HPV tests
with cytology as primary screening tests [10-12,14,21].














aEstimates based only on data from women who were screened.
bEstimates corrected for bias due to loss of follow-up.
CIN2+: cervical intraepithelial neoplasia grade 2 or worse, hrHPV: HPV testing for hi
95% CI: 95% Confidence Interval.
HPV detection was performed with Hybrid Capture 2 test (HC2; Qiagen, Gaithersburreached an overall longitudinal sensitivity of 96.3% and a
specificity of 91.4% for CIN2+ detection, the latter being
slightly lower than the one observed for cytology [13]. In
our data we observed a loss of 4.8% in longitudinal spe-
cificity when using HPV test alone compared to cytology
alone. To avoid this drop in specificity appropriate algo-
rithms must be implemented as triage tests such as re-
flex cytology or HPV genotyping for HPV16 or 18 and
others [12,13,22,23].
The cumulative detection of CIN2+ among women
with normal cytology at baseline was high for HPV posi-
tive women at baseline compared to those HPV negative
and comparable to that seen in other screening cohorts
[12,24]. Our findings suggest that the main benefit of
HPV testing is the identification of women harbouringof both tests for CIN2+ prediction
V CYTOLOGY HPV + CYTOLOGY
.8-96.1) 44.4 (39.2-49.7) 94.4 (92.8-96.1)
.8-92.2) 38.2 (33.9-42.6) 90.5 (88.8-92.2)
.4-91.2) 96.4 (95.1-97.7) 87.2 (84.6-89.7)
.5-94.5) 97.8 (97.0-98.7) 91.9 (90.3-93.5)
.4-23.3) 22.9 (16.6-29.1) 15.0 (21.6-8.5)
.0-21.1) 20.9 (15.9-25.8) 14.2 (9.1-19.3)
-100.1) 98.6 (97.8-99.5) 99.8 (99.6-100)
-100.1) 99.1 (98.5-99.6) 99.8 (99.6-100)
gh-risk types, PPV: positive predicted value, NPV: negative predicted value,
g, MD, USA).
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longer follow-up periods confirm that HPV positive wo-
men with a normal cytology harbour an increased risk in
the long run of CIN2, CIN3, and invasive CC and that
an increased over-detection of HPV tests can be ruled
out [27]. An increased number of referral tests due to an
excess of positive HPV tests in women with no disease
could be an undesired effect of this strategy [26,28]. In
three European RCTs about seven women had a poten-
tial false-positive screening result for each CIN2+ de-
tected [26]. In our study, this ratio was 6.3 women for
each CIN2+ or 14 women for each CIN3+ detected. In
the ATHENA HPV trial, a screening strategy with HPV
testing followed by a reflex cytology, resulted in 4.5 col-
poscopies per CIN2+ detected, similar to the rate of
using HPV with genotyping [29]. Total number of col-
poscopies for CIN2+ detected in screened women is
now considered a good quality indicator of overdiagnosis
[30]. However, in the POBASCAM trial, the number of
referrals in the HPV positive arm was considerably re-
duced in further screening rounds if the interval was
long enough to avoid detection of acute HPV infection
[25]. Efforts to minimize referrals should not only be an
economical aim but also a good clinical practice aim to
avoid unwanted effects of screening such as overtreat-
ment or anxiety associated to a positive test.
European RCTs and American screening cohorts have
shown that among HPV negative women, the risk for
CIN2+ was very low (0.2% and 1.2%, for women without
or with cytological abnormalities respectively) suggesting
that safe intervals can go beyond five years if a validated
HPV tests is being used [13,25,26,31,32] providing a
beneficial cost-efficacy ratio [33]. In our study, 97.8% of
the HPV negative women, irrespective of the cytology
result, the risk for CIN2 was 0.2% and 0% for CIN3+, re-
assuring a safe 3-year screening interval.
In this study we have explored the strategy to protect
poorly screened women by introducing a more complete
screening approach. However, screen negative women
were prone to a poor follow-up at 3 years as almost half
of them did not return during the follow-up period con-
sistently with that observed in other studies [14]. A be-
havioural study in the region identified that the large
majority of poorly screened women reported poor know-
ledge about the relevance of CC screening [34] indicating
that efforts to explain the benefits of screening should be
reinforced.
Due to the differential attendance to control visits
according to the screening baseline results we corrected
the accuracy parameters (i.e. sensitivity, specificity) by
follow-up estimates to minimize any bias [19]. We could
not correct for a potential verification bias as HPV-
negative women were not referred to colposcopy and bi-
opsy. But in our study, about 7% of women with negativescreening results had histological data for unknown rea-
sons to the investigators. Unfortunately we did not have
any more details on other medical reason of why these
women were biopsied. However, none of these women
were diagnosed with CIN2+. In Kulasingam et al. study,
in which random biopsies were performed in all double
negative women, no CIN2+ was reported [19]. Thus, the
data support that if there is any identification bias the
weight of it must be small.
We were concerned about the low longitudinal sensi-
tivity of the cytology test but it is well accepted that
quality of cytology depends on many factors as is ex-
tremely amenable to poor reproducibility. Although a
relevant proportion of the women were menopausal, we
did not find differences by age strata or by pathology la-
boratory but our sample size was relatively small and es-
timates by strata were unstable.
Strengths of this study are the performance of screening
and follow-up processes in many centres across Catalonia
as part of the routine CC screening. Co-testing with
cytology and HPV allowed us not only the comparison
between tests but also to speculate about different
screening scenarios as testing was done blind to the other
test result. Finally, the HPV testing used complied with its
recognized clinical validity and reproducibility [16].
Conclusions
In a group of underscreened women participating in
opportunistic screening, HPV test, as primary screening
tool, was superior to cytology for CIN2+ detection with
a higher longitudinal sensitivity over 3-year follow-up.
Both tests had a very high NPV. Primary HPV screening
followed by cytological triage could be the optimal stra-
tegy to identify CIN2+ in poor screening attenders in
developed countries leading to longer and safe screen
intervals.
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